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study to investigate the safety and efﬁcacy of two doses of
tiotropium bromide (2.5mg and 5mg) administered once daily via
the Respimat® device for 12 weeks in patients with cystic ﬁbrosis
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Tiotropium bromide is an effective bronchodilator and may have additional poten-
tially useful effects in CF. In this study 510 cystic ﬁbrosis (CF) patients were ran-
domized to 12 weeks treatment with 2.5 mg, 5mg tiotropium or placebo. 138 patients
11 years with a baseline mean FEV1 percent predicted of 94% and 372 patients
12 years with a mean baseline FEV1 percent predicted of 69% were studied.
Efﬁcacy was shown in patients treated with tiotropium (2.5 mg and 5 mg) with
statistically signiﬁcant improvement (compared with placebo) for the co primary
efﬁcacy endpoints (percent predicted FEV1 AUC0−4h response [2.5mg − 2.94%
{p = 0.001}; 5mg − 3.39% {p = 0.0001}] at the end of Week 12 and pre-dose percent
predicted FEV1 response [2.5mg − 2.24% {p = 0.0184}; 5mg − 2.22% {0.0179}]
at the end of Week 12). Volumetric changes in FEV1 AUC0−4h at Week 12 were
90mL for both 2.5mg and 5mg (p = 0.0004 and 0.0002, respectively). The overall
safety proﬁle of tiotropium was good with no unexpected safety ﬁndings. Reports
of gastrointestinal events, particularly DIOS, occurred rarely. There were a total of
3 reports of DIOS (1 in the placebo group [0.6%]; 2 in the 5 mg group [1.1%]).
This trial did not require withdrawing any medications and so tiotropium was tested
on top of standard care. In additon, there was no upper limit for FEV1 upon entry
into the trial very often resulting in near normal lung function. The present study
provides evidence of bronchodilator efﬁcacy in CF patients treated with tiotropium
(2.5mg and 5mg) once daily for 12 weeks. The safety and PK proﬁles are consistent
with the patient population and do not demonstrate any cause for concern.
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A single inhalation of nebulized L-arginine temporarily improves airway NO
production and pulmonary function in patients with CF. However, L-arginine is
also metabolized by arginase, an enzyme that forms ornithine and urea. Ornithine
is the precursor of the polyamines which may contribute to airway remodeling.
Objective: To study safety and efﬁcacy of repeated inhalations of nebulized
L-arginine in CF patients.
Methods: A double-blind, randomized, placebo-controlled crossover treatment trial
of twice daily inhalation of 500mg L-arginine for two weeks compared to saline
in 20 CF patients (NCT00405665 ClinicalTrials.gov).
Results: Nineteen patients completed the study. The inhalation of L-arginine was
well tolerated. Inhaled L-arginine did not result in an increase in sputum neutrophil
counts, Il-8 or neutrophil elastase. Exhaled NO (FENO) was signiﬁcantly increased
30 and 60 min after the ﬁrst inhalation of L-arginine (p< 0.05, respectively).
FENO remained increased after 14 days of inhaled L-arginine (p = 0.03, paired
t-test) but not placebo. FEV1 increased by an average of 65ml after 14 days of
L-arginine compared to −8ml after placebo. This difference did not reach statistical
signiﬁcance. Sputum analyses revealed an increase in ornithine concentrations after
inhaled L-arginine, but no change in sputum levels of the polyamine spermine
(1.8 vs. 2.2mmol/L, p = 0.7).
Conclusion: Repeated inhalation of L-arginine in this study was safe and well
tolerated. Inhaled L-arginine resulted in an increase in NO production but no
evidence for increased airway inﬂammation in CF patients.
This study was funded by the Canadian CF Foundation and the Irwin Family
Foundation
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Objective: Aerosolized TOBI® has been used by CF patients for years. TIP™ has a
similar clinical response to TOBI but with a shorter administration time, improving
patient satisfaction. Questions remain about durability of the clinical response due
to selection of resistant pathogens. We sought to assess the microbiological response
to TIP vs TOBI in the EAGER trial.
Methods: 517 patients with chronic Pa infection received TIP (n = 308) or TOBI
(n = 209) for 3 cycles (month on/month off). Resistance to tobramycin was based on
parenteral breakpoint criteria (minimum inhibitory concentration [MIC] >8mg/mL).
Results: At enrollment, 81% of patients had prior inhaled tobramycin use and 22%
had resistant Pa isolates. The % of resistant isolates increased when on treatment,
but decreased to baseline numbers during off-treatment periods. At study end, most
isolates had a MIC 0.5−8mg/mL (all biotypes). Despite the increase in MIC, at the
end of Cycle 3, 89.4% of TIP patients had Pa isolates with a MIC 30 times lower
than the mean tobramycin sputum concentration post TIP-inhalation. Pa sputum
density decreased during treatment periods; mean reduction (log10) at the end of
Cycle 3 was 1.61 (SD 2.03) in TIP- and 0.77 (SD 1.78) in TOBI-treated patients.
Also, lung function (FEV1% relative change) after 3 cycles improved in patients
with resistant pathogens at baseline (mean change: TIP 1.4% and TOBI 3.0%,
respectively).
Conclusion: Both TIP and TOBI reduce Pa density and improve lung function in
CF patients irrespective of baseline MIC values.
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Rationale: In CF sinonasal colonization with P. aeruginosa occurs primarily and as
chronic persistent infection. Nasal inhalation with vibrating aerosols (Pari Sinus™)
was shown to deposit drugs into paranasal sinuses. This is the ﬁrst trial on nasal
inhalation of vibrating antibiotic aerosol with the device applied in CF-patients with
chronic pulmonary colonization and detection of P. aeruginosa in nasal lavages
(NL).
Objectives: To evaluate primary endpoints and sample sizes for a principal study.
Primary endpoint was P. aeruginosa quantiﬁcation in NL. Secondary endpoints were
ENT-related QoL assessed with the Sino-Nasal-Outcome-Test 20, otologic and renal
tolerability.
Methods: Tobramycin 80mg (Gernebcin™, 2ml, 4 minutes per nostril) or NaCl
0.9% were inhaled once daily during 28 days. For the following 28 days all patients
were offered Tobramycin therapy.
Results: 9 patients participated (6 Tobramycin, 3 NaCl 0.9%; 6m; mean age
22.3 yrs). Inhalation was well tolerated (Tobramycin serum levels <0.5mg/l, stable
Creatinine levels). P. aeruginosa quantity in NL decreased in 50% (3/6) of patients
treated with Tobramycin but in none (0/3) treated with placebo (n.s.). Despite the
small cohort nasal antibiotic inhalation lead to signiﬁcant improvement of QoL
compared to NaCl 0.9% (p = 0.036).
Conclusion: Sinonnasal inhalation of vibrating antibiotic aerosols appears to be
a promising method for reduction of sinonasal symptoms and P. aeruginosa
colonization.
